Part 1 - NASH: Anticipating an impending storm - What is NASH?
In this first part, Stephen A. Harrison, MD, Medical Director of Pinnacle Clinical Research, San Antonio, introduces us to NAFLD (Non Alcoholic Fatty Liver Disease), and more specifically NASH (Non-alcoholic Steatohepatitis). He explains the definition of the disease, as well as its characteristics & the risks induced by its progression. He also highlights how the disease is related to the double epidemic of obesity and diabetes.
Part 2 - Who is at risk?
In this second part, Mary E. Rinella, MD, Associate Professor of Medicine, Northwestern University Feinberg School of Medicine, Chicago, describes in more detail who are the patients at risk of developing NAFLD (Non Alcoholic Fatty Liver Diseases)/NASH (Non-Alcoholic Steatohepatitis), the link between NASH and cardiovascular events, the ultimate consequences of the disease, and the importance of a multidisciplinary approach to be successful in the fight against NASH
Part 3 - Improving access to NASH diagnosis
In this third part, Pr. Arun J. Sanyal , MD, Virginia Commonwealth University Medical Center, Richmond, explains that NASH is under diagnosed because a biopsy is usually necessary to confirm diagnosis. Because NASH is a silent disease and most patients are asymptomatic until late stages of the disease, it is crucial that a new, easy-to-use, accessible non-invasive diagnostic tool becomes available soon.
Part 4 - How to resolve NASH?
In this fourth part, Pr Kenneth Cusi, MD, Chief of the Division of Endocrinology, Diabetes and Metabolism at the University of Florida, Gainesville, explains how beneficial weight loss is for NASH patients. But most people struggle to lose weight, and more importantly keep it off. Therefore, because of the prevalence of NASH and its rapid progression, increasing awareness around NASH could help to better manage patients, but that new treatments remain a priority.
Part 5 - Anticipating an impending storm: The future
In this last part, Pr. Vlad Ratziu, MD, Professor of Hepatology at the Pitié-Salpêtrière Hospital, Paris, explains that resolving NASH (inflammation and ballooning), the underlying cause of cirrhosis, is a recommended endpoint for clinical trials. He tells us more about the key requirements for an anti-NASH drug, especially the importance of safety and tolerability on top of efficacy.
Provided by: The NASH Education Program
Press Release
October 20, 2017
The AASLD Meeting will also be an opportunity for The NASH Education Program™ to release the full length version of an educational video involving Drs. Stephen Harrison, Mary Rinella, Arun Sanyal, Kenneth Cusi and Vlad Ratziu, that was shot during NASHTAG 2017.
The NASH Education Program™: Key Insights from the First US Survey Commissioned by the NASH Global Health Observatory™
The NASH Education ProgramTM is an endowment fund created at the end of 2016 by the biopharmaceutical company GENFIT with the objective to conduct – together with other key stakeholders committed to the fight against nonalcoholic steatohepatitis (NASH) – a series of disease awareness initiatives around NASH. Today, it publishes new results from the first survey conducted in the US for the NASH Global Health Observatory.....
Download press release or Read Online
Detailed results will be shared during the AASLD Liver Meeting®
Updates From The Liver Meeting® 2017
The Liver Meeting® - Cardiovascular Risk in Women with Fatty Liver Disease: Risk is Not Equal Opportunity
The Liver Meeting® 2017 - Can you Inherit a Fatty Liver?
Fatty liver disease fastest-growing reason for transplants in young U.S. adults
Navigate This Blog
The Liver Meeting® 2017
Patient-Friendly Links
HCV Sites With Key Data, Expert Review & Summary
No comments:
Post a Comment